London, UK: 27 April 2007 - Cancer drug developer Antisoma plc (LSE:
ASM; USOTC: ATSMY) has been notified that The Goldman Sachs Group,
Inc., no longer has a disclosable interest in the Company's shares.
+44 (0)20 8799 8200
Except for the historical information presented, certain matters
discussed in this statement are forward looking statements that are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from results, performance or
achievements expressed or implied by such statements. These risks and
uncertainties may be associated with product discovery and
development, including statements regarding the company's clinical
development programmes, the expected timing of clinical trials and
regulatory filings. Such statements are based on management's current
expectations, but actual results may differ materially.
Notes for Editors:
Background on Antisoma
Based in London, UK, Antisoma is a biopharmaceutical company that
develops novel products for the treatment of cancer. Antisoma fills
its development pipeline by acquiring promising new product
candidates from internationally recognised academic or cancer
research institutions. Its core activity is the preclinical and
clinical development of these drug candidates. Please visit
www.antisoma.co.uk for further information about Antisoma.
---END OF MESSAGE---